Related Experiment Videos
Sodium-Glucose Cotransporter 2 Inhibitors: A Scoping Review of Current Evidence, Mechanisms, and Adverse Effects
Sam Woodowrth1, Robert Hayden1
1Department of Medicine Maine Medical Center.
Abstract:
Sodium-glucose cotransporter 2 (SGLT2) inhibitors were initially developed as oral hypoglycemic agents for type 2 diabetes (T2D), but mounting evidence has solidified their role as practice-changing therapies for cardiovascular-kidney-metabolic (CKM) syndrome, which includes congestive heart failure (CHF) and chronic kidney disease (CKD). This review summarizes the pivotal randomized controlled trials evaluating SGLT2 inhibitors, highlighting their clinical efficacy, key mechanisms of action, and adverse effects. As indications continue to expand and more patients are prescribed SGLT2 inhibitors, hospitalists must have a thorough understanding of this important medication class.
Related Concept Videos
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Secondary Active Transport
Secondary Active Transport
Glucose Absorption Into the Small Intestine
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...